These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34606933)

  • 1. Terlipressin and the Treatment of Hepatorenal Syndrome: How the CONFIRM Trial Moves the Story Forward.
    Belcher JM; Parada XV; Simonetto DA; Juncos LA; Karakala N; Wadei HM; Sharma P; Regner KR; Nadim MK; Garcia-Tsao G; Velez JCQ; Parikh SM; Chung RT; Allegretti AS;
    Am J Kidney Dis; 2022 May; 79(5):737-745. PubMed ID: 34606933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
    J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
    Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
    Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatorenal Syndrome With Acute Kidney Injury: Diagnosis and Medical Management.
    Erstad BL
    Ann Pharmacother; 2024 Feb; 58(2):156-164. PubMed ID: 37271967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
    Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory events with terlipressin and albumin in hepatorenal syndrome: A review and clinical guidance.
    Allegretti AS; Subramanian RM; Francoz C; Olson JC; Cárdenas A
    Liver Int; 2022 Oct; 42(10):2124-2130. PubMed ID: 35838488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatorenal Syndrome: Pathophysiology, Diagnosis, and Treatment.
    Belcher JM
    Med Clin North Am; 2023 Jul; 107(4):781-792. PubMed ID: 37258014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terlipressin for hepatorenal syndrome.
    Wong F
    Curr Opin Gastroenterol; 2024 May; 40(3):156-163. PubMed ID: 38353275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terlipressin in the management of liver disease.
    Scheinberg AR; Martin P; Turkeltaub JA
    Expert Opin Pharmacother; 2023; 24(15):1665-1671. PubMed ID: 37535437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of terlipressin and norepinephrine for treatment of hepatorenal syndrome-acute kidney injury: A systematic review and meta-analysis.
    Olson JC; Subramanian RM
    PLoS One; 2024; 19(1):e0296690. PubMed ID: 38285703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Pharmacologic Therapies for Hepatorenal Syndrome-Acute Kidney Injury.
    Duong N; Kakadiya P; Bajaj JS
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10S):S27-S34. PubMed ID: 37625864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
    Wong F; Boyer TD; Sanyal AJ; Pappas SC; Escalante S; Jamil K
    Nephrol Dial Transplant; 2020 Sep; 35(9):1554-1561. PubMed ID: 30887050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
    Gifford FJ; Morling JR; Fallowfield JA
    Aliment Pharmacol Ther; 2017 Mar; 45(5):593-603. PubMed ID: 28052382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.
    Magan AA; Khalil AA; Ahmed MH
    World J Gastroenterol; 2010 Nov; 16(41):5139-47. PubMed ID: 21049548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.
    Facciorusso A; Chandar AK; Murad MH; Prokop LJ; Muscatiello N; Kamath PS; Singh S
    Lancet Gastroenterol Hepatol; 2017 Feb; 2(2):94-102. PubMed ID: 28403995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terlipressin versus other vasoactive drugs for hepatorenal syndrome.
    Israelsen M; Krag A; Allegretti AS; Jovani M; Goldin AH; Winter RW; Gluud LL
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011532. PubMed ID: 28953318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A; Borup T; Møller S; Bendtsen F
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Terlipressin for hepatorenal syndrome: A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Int J Artif Organs; 2009 Mar; 32(3):133-40. PubMed ID: 19440988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terlipressin in the management of adults with hepatorenal syndrome-acute kidney injury (HRS-AKI).
    Kulkarni AV; Lee J; Reddy KR
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1067-1079. PubMed ID: 37856367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.